ConductScience.org, home

Paper35308532

Favipiravir Effectiveness and Safety in Hospitalized Moderate-Severe COVID-19 Patients: Observational Prospective Multicenter Investigation in Saudi Arabia.

Al-Muhsen S and 10 others. Front Med (Lausanne), 2022. Cited by 7 papers, by iCite.

Cite this record

ConductScience Library. Favipiravir Effectiveness and Safety in Hospitalized Moderate-Severe COVID-19 Patients: Observational Prospective Multicenter Investigation in Saudi Arabia. Papers, record 35308532. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35308532

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Favipiravir Effectiveness and Safety in Hospitalized Moderate-Severe COVID-19 Patients: Observational Prospective Multicenter Investigation in Saudi Arabia.
PubMed
Journal
Front Med (Lausanne)
PubMed
Year
2022
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
7
iCite
Relative citation ratio, by iCite
0.48
iCite
Revised in PubMed
2022-03-22
PubMed

Authors11

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Al-Muhsen SSaleh
2Al-Numair NSNouf S
3Saheb Sharif-Askari NNarjes
4Basamh RRoaa
5Alyounes BBanan
6Jabaan AAmjad
7Saheb Sharif-Askari FFatemeh
8Alosaimi MFMohammed F
9Alsohime FFahad
10Halwani RRabih
11Al-Saud HHaya

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References21

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
134699552Early administration of remdesivir to COVID-19 patients associates with higher recovery rate and lower need for ICU admission: A retrospective cohort study.PLoS One2021https://conductscience.org/library/papers/34699552PubMed
232458459Neutrophil to lymphocyte ratio as prognostic and predictive factor in patients with coronavirus disease 2019: A retrospective cross-sectional study.J Med Virol2020https://conductscience.org/library/papers/32458459PubMed
333890544Effectiveness and safety of favipiravir compared to supportive care in moderately to critically ill COVID-19 patients: a retrospective study with propensity score matching sensitivity analysis.Curr Med Res Opin2021https://conductscience.org/library/papers/33890544PubMed
428769016Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase.Proc Jpn Acad Ser B Phys Biol Sci2017https://conductscience.org/library/papers/28769016PubMed
534292670Population pharmacokinetics of favipiravir in patients with COVID-19.CPT Pharmacometrics Syst Pharmacol2021https://conductscience.org/library/papers/34292670PubMed
634111191Combination of (interferon beta-1b, lopinavir/ritonavir and ribavirin) versus favipiravir in hospitalized patients with non-critical COVID-19: A cohort study.PLoS One2021https://conductscience.org/library/papers/34111191PubMed
725544306Favipiravir: a new medication for the Ebola virus disease pandemic.Disaster Med Public Health Prep2015https://conductscience.org/library/papers/25544306PubMed
833882157Japan's Drug Regulation During the COVID-19 Pandemic: Lessons From a Case Study of Favipiravir.Clin Pharmacol Ther2022https://conductscience.org/library/papers/33882157PubMed
932678530Dexamethasone in Hospitalized Patients with Covid-19.N Engl J Med2021https://conductscience.org/library/papers/32678530PubMed
1033212256Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial.Int J Infect Dis2021https://conductscience.org/library/papers/33212256PubMed
1129882740Use of Favipiravir to Treat Lassa Virus Infection in Macaques.Emerg Infect Dis2018https://conductscience.org/library/papers/29882740PubMed
1234234012Drugs repurposed for COVID-19 by virtual screening of 6,218 drugs and cell-based assay.Proc Natl Acad Sci U S A2021https://conductscience.org/library/papers/34234012PubMed
1334040117The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials.Sci Rep2021https://conductscience.org/library/papers/34040117PubMed
1420122499Conclusion about the association between valve surgery and mortality in an infective endocarditis cohort changed after adjusting for survivor bias.J Clin Epidemiol2010https://conductscience.org/library/papers/20122499PubMed
1534044777Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis.BMC Infect Dis2021https://conductscience.org/library/papers/34044777PubMed
1632979408Neutrophil-to-lymphocyte ratio on admission is an independent risk factor for the severity and mortality in patients with coronavirus disease 2019.J Infect2021https://conductscience.org/library/papers/32979408PubMed
1732346491Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study.Engineering (Beijing)2020https://conductscience.org/library/papers/32346491PubMed
1833741945Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model.Nat Commun2021https://conductscience.org/library/papers/33741945PubMed
1934319552Favipiravir and Hydroxychloroquine Combination Therapy in Patients with Moderate to Severe COVID-19 (FACCT Trial): An Open-Label, Multicenter, Randomized, Controlled Trial.Infect Dis Ther2021https://conductscience.org/library/papers/34319552PubMed
2034347191Effectiveness of favipiravir in COVID-19: a live systematic review.Eur J Clin Microbiol Infect Dis2021https://conductscience.org/library/papers/34347191PubMed

See all 21 referencesDownload CSV of references

Cited by6

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 7 citations.

PMIDTitleJournalYearIn PapersSource
40465794In-hospital mortality outcomes of favipiravir in patients with moderate to severe COVID-19 infection: An emulated target trial using real-world data from the largest field hospital in Thailand.PLoS One2025https://conductscience.org/library/papers/40465794PubMed
38770366Remdesivir versus Favipiravir in Hospitalized Patients with Moderate to Severe COVID-19 Pneumonia: A Propensity Score-Matched Retrospective Cohort Study.Int J Gen Med2024https://conductscience.org/library/papers/38770366PubMed
38665565Multiple inborn errors of type I IFN immunity in a 33-year-old male with a fatal case of COVID-19.Heliyon2024https://conductscience.org/library/papers/38665565PubMed
38086763Development of iminosugar-based glycosidase inhibitors as drug candidates for SARS-CoV-2 virus via molecular modelling and in vitro studies.J Enzyme Inhib Med Chem2024https://conductscience.org/library/papers/38086763PubMed
37153358Profiles of Independent-Comorbidity Groups in Senior COVID-19 Patients Reveal Low Fatality Associated with Standard Care and Low-Dose Hydroxychloroquine over Antivirals.J Multidiscip Healthc2023https://conductscience.org/library/papers/37153358PubMed
36271948Saliva metabolomic profile of COVID-19 patients associates with disease severity.Metabolomics2022https://conductscience.org/library/papers/36271948PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/35308532

GET https://conductscience.org/api/papers/v1/35308532/references?page=2